key: cord-0072762-q4m074gp
authors: Link, Denise
title: What Is Your STI IQ?
date: 2022-01-03
journal: J Nurse Pract
DOI: 10.1016/j.nurpra.2021.12.015
sha: 0f983f0c0ac7a5dc6b780c0b3d525bd1dfb81aef
doc_id: 72762
cord_uid: q4m074gp

nan

Quality Care for Women's Health What Is Your STI IQ? Denise Link As a result of the emergence of SARS-CoV-2 (COVID-19), preventable and treatable conditions proliferated and exacerbated. Aailability of vaccines to prevent COVID, and adherence to basic public health strategies have enabled a return to routine health care to near pre-COVID levels. We are now engaged in the task of achieving and exceeding pre-COVID performance on quality-ofcare measures. Standardization of care using guidelines produced by agencies such as the Centers for Disease Control and Prevention (CDC), whose mission is to protect the public health, is the most effective means to measure progress in achieving optimal health.

On the basis of ongoing research, a number of changes were adopted in the "Sexually Transmitted Infections Treatment Guidelines, 2021" ("the Guidelines") from the CDC. The full text of the Guidelines and a quick reference table are available on the CDC website (https://www.cdc.gov/STI/treatment-guidelines/STI-Guidelines-2021.pdf). This column focuses on those changes related to the care of women who identify by the sex assigned at birth. The Guidelines include detailed guidance on screening and treatment for special populations and alternatives to first-line treatments.

Chlamydia, gonorrhea, trichomonas, and syphilis were all on the rise before COVID-19 emerged. Screening for cervical cancer with co-testing for human papilloma virus, already on the decline, fell precipitously as routine well-woman visits were cancelled or postponed to prevent the spread of COVID-19. It should come as no surprise, then, that the prevalence of cervical dysplasia and sexually transmitted infections (STIs) has increased as new or existing conditions went undetected and untreated. The updated recommendations include new approaches to screeningdand in some cases, treatmentdin an attempt to regain lost ground on reducing the incidence of these infections and their adverse impact on health.

Because people 15 to 24 years of age still represent the largest number of people infected with chlamydia, annual screening in this population remains strongly recommended. Stigma and reluctance to disclose being sexually active are significant barriers to obtaining STI screening in this age group. Normalizing STI testing and offering opt-out testing for chlamydia, has been shown to reduce the prevalence of this infection by 55%. 1 Rather than relying on riskbased testing, in which people must report 1 or more risk behaviors to trigger a test, screening is universal. Clients are presented with 3 standard discussion points; that it is routine in the practice, allowing them to decline by asking if it is okay to test; and brief information about the potential risk to their health from untreated chlamydia. 1 In a former practice, we were experiencing an unacceptably low rate of chlamydia screening. In addition to following the opt-out discussion points, we also instituted selftesting. We gave the clients the test materials, instructed them in the procedure, and retrieved the completed test. This was carried out by the medical assistants as part of the initial intake interview before the clinician saw the patient. By following this protocol, our screening rate went from 59% to 84% in 1 year. By performing monthly reports for missed screenings using our electronic health record, with follow-up, we achieved nearly 100% compliance with the standard in the following year. I am sure that we picked up many chlamydia infections that would have otherwise remained undetected. The CDC guideline for treatment for chlamydia has changed. Instead of a single 1-g dose of oral azithromycin, the preferred regimen is now doxycycline 100 mg orally twice daily for 7 days. 2 Those of us who have been around for a while will recall that the "new" recommendation is a return to a former standard. There is a delayed-release (DR) form of doxycycline (200 mg DR), trade name Doryx that can be taken once daily, which may be less of a burden than the 7 day treatment and improve medication adherence. The cost for that new formulation is quite a bit higher than the lower dose agent ($113.00 vs $3.38) and may not be covered by pharmaceutical insurance plans. 3 Note that in pregnant women, the treatment for chlamydia remains a single 1-g dose of azithromycin.

Gonorrhea, the second most common bacterial infection reported in the United States, has become resistant to many antibiotics so that now there is only one agent recommended by the CDC. Antibiotic-resistant gonorrhea accounts for half of the infections in the United States. The preferred medication, ceftriaxone, is the same but the dose has doubled. The CDC-recommended treatment is now a single intramuscular (IM) 500-mg dose. For clients who weigh 300 pounds, the recommended dose of ceftriaxone is 1-g IM. Due to evidence that the automatic addition of azithromycin to the treatment regimen for gonorrhea has contributed to the increase in antibiotic resistance in gonorrhea and adversely affected the microbiome, this practice is no longer recommended. 3 If there is a documented cooccurring infection of chlamydia, doxycycline 100 mg twice daily for 7 days should be added.

Trichomoniasis (Trichomonas vaginalis) is the most common nonviral STI worldwide. Trichomoniasis infections adversely affect reproductive health in men and women, but women are more likely to report symptoms than men. Trichomoniasis is not a reportable disease. However, it is associated with an increase in the transmission of human immunodeficiency virus (HIV), can cause discomfort when symptomatic, and impact quality of life. 4

The Journal for Nurse Practitioners j o u r n a l h o m e p a g e : w w w . n p j o u r n a l . o r g Therefore, it is important to screen for this infection and complete a pertinent health history and review of symptoms, physical assessment, and lab testing. Preferred treatment for confirmed cases of T. vaginalis infection is determined on the basis of sex. Although adequate treatment for men remains 2 g of metronidazole orally in a single dose, the CDC advises that women be prescribed metronidazole 500 mg orally twice daily for 7 days. Metronidazole 500 mg orally or intravenously twice daily has been added to the regimen for the treatment of pelvic inflammatory disease based on evidence that adding an agent that is effective against anerobic organisms improves outcomes. 2 Alternative regimens and pharmaceutical management of recurrent or refractory infections, and treatment of trichomoniasis in pregnancy are detailed in the Guidelines. 2 Based on a lack of supporting evidence, the advice to refrain from alcohol while on an nitroimidazole has been deleted.

The number of syphilis cases has been surging in the past 2 decades, doubling with each data review every five years. Congenital syphilis, a completely preventable condition in newborns if treated as late as the third trimester of pregnancy, quadrupled between 2014 and 2019. 5 Because of the increase and the serious consequences for the health of the mother and infant, including stillbirth, early and repeat screening is recommended during pregnancy. A test for syphilis should be included in the prenatal care panel of tests done at the first visit. In populations with low prenatal care attendance, a test for syphilis should be done at the time that pregnancy is diagnosed, even if the test is done at an office other than where prenatal care is provided. The CDC recommends testing again twice during the third trimester: at 28 weeks' gestation and at the time of labor/birth. There are several tests that may be used to screen for syphilis. Two nontreponemal tests, Rapid Plasma Reagin (RPR) and Venereal Disease Research Laboratory (VDRL), detect reaction to antibodies that are present in most patients with syphilis. Treponemal assaysdfluorescent treponemal antibody absorption (FTA-ABS), Treponema pallidum particle agglutination (TP-PA), enzyme immunoassay (EIA), and multiplex flow immunoassay (MFI)didentify specific antibodies directed against the pathogen responsible for syphilis infection, T. pallidum. There are two protocols used by labs for screening, a "traditional" process in which a nontreponemal test is performed first, followed by a treponemal test to confirm positive results. This is the sequence followed by the majority of low-volume commercial labs that serve a population with low prevalence of syphilis. Labs used by providers who do a high volume of tests or serve a high-risk population use "reverse sequence" in which the treponemal test is performed first, followed by a nontreponemal confirmatory test. In this process, positive treponemal tests with a negative nontreponemal test should be confirmed by a different treponemal assay than initially used. Ortiz and colleagues 6 completed a systematic literature review to provide guidance for clinicians on when to use one or the other screening algorithm. On the basis of their findings, the authors advise that there are valid arguments to be made for each approach. Clinicians should be guided in their selection of reference lab by the level of risk in the population served and consequences of a missed diagnosis. In the case of prenatal screening for syphilis, where congenital syphilis is a concern, the authors recommend more frequent screening using either protocol, which supports the CDC recommendation. The treatment protocols for syphilis have not changed since the last publication of the Guidelines.

Lastly, the Guidelines now include information regarding testing and treatment for Mycoplasma genitalium. There is a detailed review of the literature provided to support the recommendations. Testing by culture takes several months 2 ; nucleic acid amplification tests (NAAT) that detect and identify organisms by their unique nucleic acid sequence are the preferred assays. Testing for M. genitalium is only recommended for women with persistent or recurrent cervicitis or confirmed pelvic inflammatory disease; asymptomatic screening is discouraged. Because there is significant resistance to both macrolides and quinolones, 2-stage therapy is recommended. Resistance testingeguided treatment is preferred if available. In all cases, doxycycline 100 mg twice daily for 7 days is initial therapy. If macrolide sensitive, follow with a single 1-g dose of azithromycin, then azithromycin 500 mg daily for 3 days. If resistance testing is not available, follow the initial doxycycline regimen with moxifloxacin 400 mg daily for 7 days. 2 

Chlamydia screening post COVID-19

Sexually transmitted diseases treatment guidelines

Extra! Extra! Read all about it! 2021 guideline updates for treatment of chlamydia uncomplicated gonorrhea

In case you missed it! Trichomoniasis treatment update 2021

Syphilis is resurging in the U.S., a sign of public health's funding crisis. Health Shots. 2021

The traditional or reverse algorithm for diagnosis of syphilis: pros and cons

is a clinical professor emerita at Arizona State University Edson College of Nursing and Health Innovation